Upper Tract Urothelial Carcinoma: From the Editor
An Update on Upper Tract Urothelial Carcinoma
Low-grade upper tract urothelial carcinoma (UTUC) comprises a substantial percentage of UTUCs. While mortality risk is low, diagnostic choices, therapeutic care, and continued management of these carcinomas are complex decisions. Low-grade UTUC can cause hematuria and urinary obstruction, and tumors tend to recur. Periodic radiographic imaging is required as well as ureteroscopic interventions not only to treat disease, but also to monitor for recurrence.
An Update on Low-Grade Upper Tract Urothelial Carcinoma
FDA Approval of Mitomycin: A New Way to Treat Upper Tract Urothelial Carcinoma
As the entire world continues to battle the COVID-19 virus, current research endeavors in so many different areas have inevitably slowed but fortunately, progress in pushing forward completed research provides hope for patients. This quote from the FDA website reinforces this commitment:
2019 Updates in Upper Tract Urothelial Carcinoma
Targetable mutations in UTUC: At the Fred Hutchinson Cancer Research Center and the University of Washington, Dr. Brian R. Winters, Dr. Andrew